Are You Over Committing to Your EU MDR Post Market Surveillance Plan?

By |2021-07-10T17:47:43+00:00March 12th, 2021|

  Overview The EU MDR and IVDR will usher in increased post-market surveillance (PMS) requirements for all MedTech companies. A PMS plan will incorporate a Post-Market Clinical Follow-up (PMCF) plan or justification for why it is unnecessary. Higher-risk devices and IVDs will require a Periodic Safety Update Report (PSUR). While for lower-class devices, a [...]

Classifying Software as Medical Device in EU MDR

By |2021-07-10T17:22:59+00:00March 9th, 2021|

Introduction to Software as a Medical Device in MDR The MDCG’s Guidance document defines the criteria for software qualification falling within the scope of the EU MDR and IVDR. This doc even seeks to elucidate which software will be considered a medical device (qualification) and its subsequent risk classification (classification). Although it is not [...]

How to Hire a Literature Search (or CER) Writer and What to Look For?

By |2021-07-11T17:00:08+00:00January 27th, 2021|

INTRODUCTION A literature search is a deliberate and efficient search from already distributed information to distinguish between a good quality reference on a particular topic. There are different reasons for conducting a literature search, including drawing information for making evidence-based reports, academic assessment, and a step in the research methods. A thorough literature search [...]

UK details a Post-Brexit Medical Device Regime Starting January

By |2021-07-11T17:26:46+00:00December 14th, 2020|

With ongoing negotiations over a trade deal between the UK and the EU and less than 30 days until the end of the Brexit transition period, the UK Government continues to flesh out guidance on regulating medical devices. Given the current circumstances, the Brexit transition period will end without a trade deal in place [...]

Post-Brexit Medical Device Regulatory Compliance – UK MHRA Guidance

By |2021-07-13T05:08:50+00:00November 26th, 2020|

What the Medicines and Healthcare products Regulatory Agency does MHRA is an executive agency sponsored by the Department of Health and Social Care. The Medicine and Healthcare products Regulatory Agency regulates medicines and devices for transfusion in the UK. MHRA regulates medicines, medical devices, and blood components. Following the UK Medicines and Healthcare products [...]

An Understanding of the Clinical Evaluation Process in China – Comparison with EU MDR

By |2021-07-11T00:32:21+00:00September 17th, 2020|

Medical device regulations in China are often likened to the European Union (EU)’s MDR, with a vital prerequisite of Clinical Evaluation Reports (CERs), as required by China’s National Medical Products Administration NMPA (formerly CFDA). Although both the aforementioned regulatory frameworks permit the use of equivalent devices as a basis for clinical data for a [...]

Guidance on the classification of Medical Device Software (MDSW) for EU MDR

By |2021-07-11T02:27:33+00:00July 15th, 2020|

Medical Device Software (MDSW) The MDSW is defined as a Medical Device regardless of its location of use. Software that is driving or influencing the use of a medical device can qualify as a device. Software intended to process, analyze, create or modify medical information could be considered medical device software if it has [...]

Post Market Clinical Follow-Up (PMCF) – Understanding MDCG’s Latest Guidance

By |2021-05-03T17:33:29+00:00June 30th, 2020|

PMCF Guidance An important constituent of Post Market Surveillance (PMS), Post Market Clinical Follow Up (PMCF) is a continuous lifecycle process, wherein the device’s clinical evaluation is constantly updated, confirming its safety and clinical performance throughout its expected lifetime. Since the requirements are said to increase under the MDR, this would necessitate prudent, thorough [...]

IVDR Part II – Your Technical Documentation and Performance Evaluation

By |2021-03-09T19:11:28+00:00June 12th, 2020|

IVDR Part II - Your Technical Documentation and Performance Evaluation In the previous article we had discussed some of the major changes to be considered in the EU IVDR; namely increased regulatory oversight, expanded clinical evidence requirements, greater requirements for IVD manufacturers and intensified supervision of Notified Bodies.  This article drills further down into [...]

Go to Top